Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 19/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 10/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6879908 | 0.90 | HCRTR2 (0.39) | HCRTR2HCRTR1CNR1 | |
| SCHEMBL6879902 | 0.87 | HCRTR2 (0.45) | HCRTR2HCRTR1 | |
| SCHEMBL6881347 | 0.86 | GAA (0.42) | HCRTR2HCRTR1 | |
| SCHEMBL6879904 | 0.80 | CHRNA7 (0.39) | — | |
| SCHEMBL14777464 | 0.78 | KMT2A (0.45) | HCRTR2HCRTR1CNR1 | |
| SCHEMBL2224696 | 0.77 | FABP1 (0.45) | HCRTR2HCRTR1CNR1 | |
| SCHEMBL2225258 | 0.76 | CNR1 (0.43) | HCRTR2HCRTR1CNR1 | |
| SCHEMBL6881351 | 0.76 | MEN1 (0.40) | HCRTR2HCRTR1CNR1 | |
| SCHEMBL6881197 | 0.76 | GAA (0.48) | HCRTR2HCRTR1 | |
| Hydrochloric Acid SCHEMBL14777519 | 0.76 | CNR1 (0.43) | HCRTR2HCRTR1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697703-B2 | Piperazine derivatives for blocking Cav2.2 calcium channels | Convergence Pharmaceuticals Limited (GB) | 2014-04-15 | — | — | US | claimed |
| EP-2533782-B1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | CONVERGENCE PHARMACEUTICALS (GB) | 2014-09-24 | — | — | EP | disclosed |
| EP-2533782-B1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | CONVERGENCE PHARMACEUTICALS (GB) | 2014-09-24 | — | — | EP | disclosed |
| US-8697703-B2 | Piperazine derivatives for blocking Cav2.2 calcium channels | Convergence Pharmaceuticals Limited (GB) | 2014-04-15 | — | — | US | disclosed |
| US-20130072499-A1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | Convergence Pharmaceuticals Limited | 2013-03-21 | — | — | US | disclosed |
| US-20130072499-A1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | Convergence Pharmaceuticals Limited | 2013-03-21 | — | — | US | disclosed |
| US-20130072499-A1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | Convergence Pharmaceuticals Limited | 2013-03-21 | — | — | US | disclosed |
| WO-2011086377-A1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072499-A1 | PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS | CACNA1B, CACNB2, CACNA1C | HCRTR2 457/4885HCRTR1 1701/4885CNR1 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.